CPT code 84432 represents a laboratory assay for thyroglobulin, a thyroid-specific protein commonly used as a tumor marker to monitor patients after treatment for differentiated thyroid cancer. Nationally, thyroglobulin testing is clinically important for detecting residual or recurrent disease and guiding surveillance strategies, making the code relevant for payers, laboratories, and clinicians involved in endocrine and oncology care.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication reviews coverage and billing considerations across major commercial and federal payers and highlights common modifiers used with laboratory services. It provides clinical context on when thyroglobulin testing is typically ordered and where the service is performed.

Readers will find a concise overview of the clinical utility of the test, the service type (clinical laboratory tumor marker assay), typical site of service (clinical or hospital laboratory), and what to expect in payer handling and billing workflows. The piece also outlines benchmarking and policy-relevant topics that affect reimbursement and utilization management for thyroglobulin testing. Data not provided in the source material are noted as unavailable.